Search This Blog

Tuesday, February 5, 2019

Rexahn price target lowered to $10 from $17 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis lowered his price target for Rexahn Pharmaceuticals to $10 following the company’s equity raise and keeps a Buy rating on the shares.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)